

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		Application No.	10/621,009
		Filing Date	July 15, 2003
		First Named Inventor	Bob D. Brown
		Art Unit	1634
(Multiple sheets used when necessary)		Examiner	Jeanine Anne Goldberg
SEP 06 2005 SHEET 1 OF 3		Attorney Docket No.	GENP.002C2

O I P E T A R C  
P A T E N T & T R A D E M A R K O F F I C E

**Y7 U.S. PATENT DOCUMENTS**

Examiner Initials	Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
JG	1	5,623,065	4/1/1997	Cook et al.	
	2	5,646,042	7/1/1997	Stincomb et al.	
	3	5,872,242	2/1999	Monia et al.	
	4	5,898,031	4/1999	Crooke, Stanley T.	
	5	5,929,040	7/1/1999	Werther et al.	
	6	6,077,833	6/2000	Bennett et al.	
	7	6,107,094	8/2000	Crooke, Stanley T.	
	8	6,172,216	1/1/2001	Bennett et al.	
	9	6,197,556	2/1/2001	Ulanovsky et al.	
	10	6,287,772	9/1/2001	Stefano et al.	
	11	6,346,938	2/2002	Pavco et al.	
	12	6,379,932 B1	04/30/02	Arnold et al.	
	13	6,380,368	4/2002	Froehler et al.	
	14	6,391,593 B1	05/2002	Weston et al.	
	15	6,451,588 B1	09/2002	Egholm et al.	
	16	6,465,193	10/1/2002	Akeson et al.	
	17	6,518,017	02/11/03	Brown et al.	
	18	6,905,820	06/1/2005	Uhlmann et al.	
	19	09/931732	8/16/2001	Brown et al.	
	20	09/932129	8/16/2001	Brown, Bob D.	
	21	10/142566	5/8/2002	Riley et al.	
	22	10/142666	5/8/2002	Brown et al.	
	23	10/142729	5/8/2005	Brown et al.	
	24	10/375504	2/25/2003	Brown et al.	
▼	25	10/621009	7/15/2003	Brown, Bob D.	

**FOREIGN PATENT DOCUMENTS**

Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T <sup>1</sup>

Examiner Signature	/Jeanine Goldberg/	Date Considered	12/27/2005
--------------------	--------------------	-----------------	------------

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

T<sup>1</sup> - Place a check mark in this area when an English language Translation is attached.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		Application No.	10/621,009
		Filing Date	July 15, 2003
		First Named Inventor	Bob D. Brown
		Art Unit	1634
(Multiple sheets used when necessary)		Examiner	Jeanine Anne Goldberg
SHEET 2 OF 3		Attorney Docket No.	GENP.002C2

Y7 U.S. PATENT DOCUMENTS					
Examiner Initials	Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
JG	26	WO 93/10103	5/27/1993	Watson et al.	
	27	WO 94/06810	3/31/1994	Bergstrom	
	28	WO 94/09129	4/28/1994	Torrence et al.	
	29	WO 95/01985	1/19/1995	Gryaznov	
	30	WO 97/18312	5/22/1997	Ludwig et al.	
	31	WO 97/26270	7/24/1997	Wincott et al.	
	32	WO 97/33991	9/18/1997	Werner et al.	
	33	WO 98/58057	12/23/1998	Ludwig et al.	
	34	Copy of PCT International Search Report, PCT/US00/09293 in 4 pages	8/8/2000		
	35	Copy of PCT International Preliminary Examination Report, PCT/US00/09293 in 6 pages	6/29/2001		
	36	Copy of Supplementary Partial European Search Report, EP 00 92 1855 in 9 pages	9/19/2003		
	37	Copy of PCT International Search Report, PCT/US00/09230 in 5 pages	7/24/2000		
	38	Copy of PCT International Preliminary Examination Report, PCT/US98/20361 in 7 pages	1/20/2000		
	39	Copy of PCT International Search Report, PCT/US98/20361 in 5 pages	2/2/1999		
	40	Copy of Supplementary Partial European Search Report, EP 98 94 8573 in 5 pages	10/15/2004		
▼	41	Copy of International Search Report, PCT/US93/10103 in 2 pages	7/4/1998		

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T <sup>1</sup>
JG	42	Agrawal et al. Antisense therapeutics: Is it as simple as complementary base recognition? Molecular Medicine Today, 2000 Vp., 6:72-81		

Examiner Signature	/Jeanine Goldberg/	Date Considered	12/27/2005
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

T<sup>1</sup> - Place a check mark in this area when an English language Translation is attached.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		<b>Application No.</b>	10/621,009
		<b>Filing Date</b>	July 15, 2003
		<b>First Named Inventor</b>	Bob D. Brown
		<b>Art Unit</b>	1634
<i>(Multiple sheets used when necessary)</i>		<b>Examiner</b>	Jeanine Anne Goldberg
<b>SHEET 3 OF 3</b>		<b>Attorney Docket No.</b>	GENP.002C2

<b>NON PATENT LITERATURE DOCUMENTS</b>			
<b>Examiner Initials</b>	<b>Cite No.</b>	<b>Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.</b>	<b>T<sup>1</sup></b>
JG	43	Altmann et al., "Novel Chemistry," <i>Applied Oligonucleotide Technology</i> , Chapter 4, pp. 73-107 (1998)	
	44	Branch, AD. A good antisense molecule is hard to find. <i>TIBS</i> , 1998 Vol. 23:45-50.	
	45	Deb et al. RNA-Dependent Protein Kinase PKR is required for activation of NF-kappa B by IFN-gamma in a STAT1-independent pathway. <i>Journal of Immunology</i> , 2001 Vol. 166:6170-6180	
	46	Hill et al., "Polymerase recognition of synthetic oligodeoxyribonucleotides incorporation degenerate pyrimidine and purine bases," <i>Proc. Natl. Acad. Sci. USA</i> , 95:4258-4263 (1998)	
	47	Jen et al. Suppression of gene expression by targeted disruption of messenger RNA: available options and current strategies. <i>Stem Cells</i> , 2000 Vol. 18:307-319	
	48	Kuwabara et al. "Activities of tRNA-embedded dimeric minizymes." <i>Nucleic Acids Symposium Series</i> , no. 37: 307-308 (1997).	
	49	Parker et al., "Ribozymes: Principles and Designs for Their Use as Antisense and therapeutic Agents," <i>Gene Regulation: Biology of Antisense RNA and DNA</i> , New York, <i>Raven Press</i> , pp. 55-70 (1992)	
	50	Sanghvi, "Heterocyclic Base Modifications in Nucleic Acids and Their Applications in Antisense Oligonucleotides," <i>Antisense Research and Applications</i> , CRC Press, GB, Chapter 15, pp. 273-288 (1993)	
	51	Thomson et al. "Universal base analogs in antisense oligodeoxynucleotides (as ODNs) : A therapeutic strategy against HIV variability," <i>American Society for Microbiology</i> , pg. 143 (1995)	
↓	52	Tidd, Ed D.M.. "Ribonuclease H-Mediated Antisense Effects of Oligonucleotides and Controls for Antisense Experiments," <i>Applied Antisense Oligonucleotide Technology</i> , pp161-171 (1998)	

1828194/072205

Examiner Signature	/Jeanine Goldberg/	Date Considered	12/27/2005
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

T<sup>1</sup> - Place a check mark in this area when an English language Translation is attached.